Status:
UNKNOWN
Evaluation Of Serum MIF Level in SLE Patients
Lead Sponsor:
Assiut University
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
Systemic lupus erythematosis (SLE) is a chronic autoimmune disease characterized by production of autoantibodies and the deposition of immune complexes, affecting a wide range of organs. The clinical ...
Eligibility Criteria
Inclusion
- Adult SLE patients \>18 years
- fulfilled the 2012 systemic lupus international collaborating clinics (SLICC) criteria
Exclusion
- Patients with overlap syndrome, pregnancy, active infection, diseases other than SLE that might produce abnormal proteinuria.
- Individuals with other autoimmune diseases (rheumatoid arthritis, dermatomyositis, scleroderma, mixed connective tissue disease).
Key Trial Info
Start Date :
February 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 28 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05253638
Start Date
February 22 2022
End Date
December 28 2022
Last Update
February 24 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.